NVO logo

Novo Nordisk A/S (NVO) Selling, General & Administrative Expenses

Annual SGA

$9.78 B
+$832.47 M+9.31%

December 31, 2024

Summary

Performance

1-Year Change

+9.31%

3-Year Change

+49.63%

5-Year Change

+81.96%

15-Year Change

+99.92%

NVO SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

98.95%
NVO annual SGA is higher than 98.95% of companies in Healthcare sector

High & Low

All-time High

$9.78 B
NVO annual SGA is currently at an all-time high

3-Year Low

$6.53 B
NVO annual SGA is currently +49.63% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
NVO previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
NVO next annual earnings announcement has not yet been scheduled

OtherNVOexpensesmetrics:

Annual Total Expenses

$23.51 B
NVO annual total expenses is $23.51 billion

Annual Operating Expenses

$17.05 B
NVO annual total operating expenses is $17.05 billion

Annual Cost Of Goods Sold

$6.46 B
NVO annual cost of goods sold is $6.46 billion

Annual Interest Expense

$237.95 M
NVO annual interest expense is $237.95 million

Quarterly SGA

$2.90 B
+$452.71 M+18.51%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+24.77%

3-Year Change

+46.94%

5-Year Change

+81.49%

NVO Quarterly SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

99.15%
NVO quarterly SGA is higher than 99.15% of companies in Healthcare sector

High & Low

All-time High

$2.90 B
NVO quarterly SGA is currently at an all-time high

3-Year Low

$1.68 B
NVO quarterly SGA is currently +72.24% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
NVO previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

N/A
NVO next earnings announcement has not yet been scheduled

OtherNVOexpensesmetrics:

Quarterly Total Expenses

$6.99 B
NVO quarterly total expenses is $6.99 billion

Quarterly Operating Expenses

$5.13 B
NVO quarterly total operating expenses is $5.13 billion

Quarterly Cost Of Goods Sold

$1.86 B
NVO quarterly cost of goods sold is $1.86 billion

Quarterly Interest Expense

-$87.59 M
NVO quarterly interest expense is -$87.59 million

TTM SGA

$68.80 B
+$4.59 B+7.14%

December 31, 2024

Summary

Performance

3-Month Change

+604.6%

1-Year Change

+650.68%

3-Year Change

+956.44%

5-Year Change

+1181.86%

NVO TTM SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

99.26%
NVO TTM SGA is higher than 99.26% of companies in Healthcare sector

High & Low

All-time High

$68.80 B
NVO TTM SGA is currently at an all-time high

3-Year Low

$40.97 B
NVO TTM SGA is currently +67.95% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
NVO previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

N/A
NVO next earnings announcement has not yet been scheduled

OtherNVOexpensesmetrics:

Annual Total Expenses

$23.51 B
NVO annual total expenses is $23.51 billion

Annual Operating Expenses

$17.05 B
NVO annual total operating expenses is $17.05 billion

TTM Cost Of Goods Sold

$6.45 B
NVO TTM cost of goods sold is $6.45 billion

TTM Interest Expense

$560.96 M
NVO TTM interest expense is $560.96 million

Selling, General & Administrative Expenses Formula

SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development

Annual SGA

$9.78 B
NVO annual SGA is $9.78 billion

Annual Operating Expenses

$17.05 B
NVO annual total operating expenses is $17.05 billion

Annual Cost Of Goods Sold

$6.46 B
NVO annual cost of goods sold is $6.46 billion

NVO Selling, General & Administrative Expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+9.3%+24.8%+650.7%
3 y3 years+49.6%+46.9%+956.4%
5 y5 years+82.0%+81.5%+1181.9%

NVO Selling, General & Administrative Expenses Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+49.6%at high+72.2%at high+68.0%
5 y5-yearat high+82.0%at high+138.6%at high+115.0%
alltimeall timeat high+9860.2%at high+639.6%at high>+9999.0%

Novo Nordisk A/S Selling, General & Administrative Expenses History

DateAnnualQuarterlyTTM
Dec 2024
$9.78 B(+9.3%)
$2.90 B(+18.5%)
$9.77 B(+2.2%)
Sep 2024
-
$2.45 B(+5.3%)
$9.56 B(+4.3%)
Jun 2024
-
$2.32 B(+10.6%)
$9.17 B(+0.8%)
Mar 2024
-
$2.10 B(-21.9%)
$9.10 B(+1.7%)
Dec 2023
$8.94 B(+24.5%)
$2.69 B(+30.8%)
$8.94 B(+7.4%)
Sep 2023
-
$2.06 B(-8.8%)
$8.33 B(+4.4%)
Jun 2023
-
$2.25 B(+15.9%)
$7.98 B(+7.5%)
Mar 2023
-
$1.94 B(-6.3%)
$7.42 B(+3.7%)
Dec 2022
$7.19 B(+10.0%)
$2.07 B(+21.5%)
$7.16 B(+1.5%)
Sep 2022
-
$1.71 B(+0.8%)
$7.06 B(+1.4%)
Jun 2022
-
$1.69 B(+0.7%)
$6.96 B(+3.7%)
Mar 2022
-
$1.68 B(-14.7%)
$6.71 B(+3.0%)
Dec 2021
$6.53 B(+15.6%)
$1.97 B(+22.6%)
$6.51 B(+3.4%)
Sep 2021
-
$1.61 B(+11.4%)
$6.30 B(+2.7%)
Jun 2021
-
$1.44 B(-3.1%)
$6.13 B(+3.9%)
Mar 2021
-
$1.49 B(-15.2%)
$5.90 B(+4.1%)
Dec 2020
$5.65 B(+5.2%)
$1.76 B(+21.8%)
$5.67 B(+2.9%)
Sep 2020
-
$1.44 B(+18.7%)
$5.51 B(+2.5%)
Jun 2020
-
$1.21 B(-3.4%)
$5.38 B(-1.0%)
Mar 2020
-
$1.26 B(-21.3%)
$5.43 B(+1.1%)
Dec 2019
$5.37 B(+1.8%)
$1.60 B(+22.2%)
$5.37 B(+1.3%)
Sep 2019
-
$1.31 B(+3.0%)
$5.30 B(+0.9%)
Jun 2019
-
$1.27 B(+6.1%)
$5.25 B(-0.1%)
Mar 2019
-
$1.20 B(-21.8%)
$5.25 B(-0.2%)
Dec 2018
$5.28 B(+7.9%)
$1.53 B(+21.6%)
$5.26 B(+0.7%)
Sep 2018
-
$1.26 B(-1.2%)
$5.23 B(+1.7%)
Jun 2018
-
$1.27 B(+5.4%)
$5.14 B(+2.9%)
Mar 2018
-
$1.21 B(-19.0%)
$4.99 B(+2.1%)
Dec 2017
$4.89 B(+1.7%)
$1.49 B(+27.5%)
$4.89 B(+3.7%)
Sep 2017
-
$1.17 B(+3.7%)
$4.71 B(-0.3%)
Jun 2017
-
$1.13 B(+2.1%)
$4.73 B(-1.0%)
Mar 2017
-
$1.10 B(-16.2%)
$4.77 B(-0.6%)
Dec 2016
$4.81 B(+0.4%)
$1.32 B(+11.4%)
$4.80 B(-0.7%)
Sep 2016
-
$1.18 B(+0.5%)
$4.84 B(+0.1%)
Jun 2016
-
$1.18 B(+3.9%)
$4.83 B(-0.4%)
Mar 2016
-
$1.13 B(-16.2%)
$4.85 B(+1.5%)
Dec 2015
$4.79 B(+0.3%)
$1.35 B(+14.7%)
$4.78 B(+1.1%)
Sep 2015
-
$1.18 B(-1.4%)
$4.73 B(-0.6%)
Jun 2015
-
$1.19 B(+12.6%)
$4.76 B(+0.6%)
Mar 2015
-
$1.06 B(-18.4%)
$4.73 B(-0.4%)
Dec 2014
$4.77 B(-0.3%)
$1.30 B(+8.0%)
$4.75 B(-1.6%)
Sep 2014
-
$1.20 B(+3.1%)
$4.83 B(+1.6%)
Jun 2014
-
$1.17 B(+8.0%)
$4.76 B(+0.1%)
Mar 2014
-
$1.08 B(-21.6%)
$4.75 B(-0.8%)
Dec 2013
$4.79 B(+11.5%)
$1.38 B(+22.2%)
$4.79 B(+2.8%)
Sep 2013
-
$1.13 B(-3.1%)
$4.66 B(+2.4%)
Jun 2013
-
$1.16 B(+4.0%)
$4.55 B(+3.0%)
Mar 2013
-
$1.12 B(-10.3%)
$4.42 B(+3.0%)
Dec 2012
$4.29 B
$1.25 B(+22.7%)
$4.29 B(+2.5%)
Sep 2012
-
$1.02 B(-1.4%)
$4.19 B(-0.6%)
Jun 2012
-
$1.03 B(+4.1%)
$4.21 B(-0.3%)
DateAnnualQuarterlyTTM
Mar 2012
-
$992.02 M(-13.2%)
$4.22 B(+1.7%)
Dec 2011
$4.16 B(+9.8%)
$1.14 B(+9.3%)
$4.15 B(+2.9%)
Sep 2011
-
$1.05 B(+0.1%)
$4.04 B(+2.6%)
Jun 2011
-
$1.04 B(+13.5%)
$3.93 B(+5.3%)
Mar 2011
-
$920.28 M(-10.2%)
$3.73 B(+1.3%)
Dec 2010
$3.78 B(+11.2%)
$1.03 B(+8.7%)
$3.69 B(+2.2%)
Sep 2010
-
$943.37 M(+11.6%)
$3.61 B(+3.9%)
Jun 2010
-
$845.64 M(-3.1%)
$3.47 B(+0.9%)
Mar 2010
-
$873.00 M(-7.7%)
$3.44 B(+2.9%)
Dec 2009
$3.40 B(+9.2%)
$945.33 M(+17.1%)
$3.34 B(+2.8%)
Sep 2009
-
$807.16 M(-0.9%)
$3.25 B(+1.7%)
Jun 2009
-
$814.67 M(+4.8%)
$3.20 B(+0.5%)
Mar 2009
-
$777.37 M(-9.1%)
$3.18 B(+2.3%)
Dec 2008
$3.12 B(+13.8%)
$855.36 M(+13.7%)
$3.11 B(+3.1%)
Sep 2008
-
$752.01 M(-5.7%)
$3.02 B(+2.9%)
Jun 2008
-
$797.24 M(+12.9%)
$2.93 B(+4.5%)
Mar 2008
-
$706.36 M(-7.2%)
$2.81 B(+2.3%)
Dec 2007
$2.74 B(+16.2%)
$761.31 M(+14.0%)
$2.74 B(+2.8%)
Sep 2007
-
$667.56 M(-0.5%)
$2.67 B(+4.0%)
Jun 2007
-
$670.85 M(+4.2%)
$2.57 B(+3.9%)
Mar 2007
-
$643.69 M(-6.4%)
$2.47 B(+8.1%)
Dec 2006
$2.36 B(+19.7%)
$687.64 M(+21.8%)
$2.29 B(+6.1%)
Sep 2006
-
$564.58 M(-1.8%)
$2.16 B(+4.0%)
Jun 2006
-
$574.78 M(+25.1%)
$2.07 B(+5.8%)
Mar 2006
-
$459.45 M(-17.5%)
$1.96 B(-0.1%)
Dec 2005
$1.97 B(+14.4%)
$556.96 M(+15.5%)
$1.96 B(+1.9%)
Sep 2005
-
$482.02 M(+4.3%)
$1.93 B(+3.5%)
Jun 2005
-
$462.04 M(+0.0%)
$1.86 B(+3.9%)
Mar 2005
-
$461.96 M(-11.2%)
$1.79 B(+3.6%)
Dec 2004
$1.72 B(+16.9%)
$520.51 M(+24.7%)
$1.73 B(+43.1%)
Sep 2004
-
$417.37 M(+6.5%)
$1.21 B(+52.8%)
Jun 2004
-
$391.82 M(-1.9%)
$791.13 M(+98.1%)
Mar 2004
-
$399.31 M
$399.31 M
Dec 2003
$1.47 B(+22.8%)
-
-
Dec 2002
$1.20 B(+10.1%)
-
-
Dec 2001
$1.09 B(+10.7%)
-
-
Dec 2000
$983.27 M(+7.8%)
-
-
Dec 1999
$911.84 M(+13.8%)
-
-
Dec 1998
$801.53 M(-12.2%)
-
-
Dec 1997
$912.47 M(-31.2%)
-
-
Dec 1996
$1.33 B(+8.0%)
-
-
Dec 1995
$1.23 B(+14.7%)
-
-
Dec 1994
$1.07 B(+73.4%)
-
-
Dec 1993
$616.94 M(-40.9%)
-
-
Dec 1992
$1.04 B(+119.3%)
-
-
Dec 1991
$476.29 M(+11.6%)
-
-
Dec 1990
$426.67 M(+33.5%)
-
-
Dec 1989
$319.57 M(+29.8%)
-
-
Dec 1988
$246.13 M(+10.3%)
-
-
Dec 1987
$223.06 M(+103.6%)
-
-
Dec 1985
$109.57 M(+11.6%)
-
-
Dec 1984
$98.15 M
-
-

FAQ

  • What is Novo Nordisk A/S annual SGA?
  • What is the all time high annual SGA for Novo Nordisk A/S?
  • What is Novo Nordisk A/S annual SGA year-on-year change?
  • What is Novo Nordisk A/S quarterly SGA?
  • What is the all time high quarterly SGA for Novo Nordisk A/S?
  • What is Novo Nordisk A/S quarterly SGA year-on-year change?
  • What is Novo Nordisk A/S TTM SGA?
  • What is the all time high TTM SGA for Novo Nordisk A/S?
  • What is Novo Nordisk A/S TTM SGA year-on-year change?

What is Novo Nordisk A/S annual SGA?

The current annual SGA of NVO is $9.78 B

What is the all time high annual SGA for Novo Nordisk A/S?

Novo Nordisk A/S all-time high annual SGA is $9.78 B

What is Novo Nordisk A/S annual SGA year-on-year change?

Over the past year, NVO annual SGA has changed by +$832.47 M (+9.31%)

What is Novo Nordisk A/S quarterly SGA?

The current quarterly SGA of NVO is $2.90 B

What is the all time high quarterly SGA for Novo Nordisk A/S?

Novo Nordisk A/S all-time high quarterly SGA is $2.90 B

What is Novo Nordisk A/S quarterly SGA year-on-year change?

Over the past year, NVO quarterly SGA has changed by +$575.25 M (+24.77%)

What is Novo Nordisk A/S TTM SGA?

The current TTM SGA of NVO is $68.80 B

What is the all time high TTM SGA for Novo Nordisk A/S?

Novo Nordisk A/S all-time high TTM SGA is $68.80 B

What is Novo Nordisk A/S TTM SGA year-on-year change?

Over the past year, NVO TTM SGA has changed by +$59.64 B (+650.68%)